HC Wainwright Has Negative Forecast for PTGX Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Protagonist Therapeutics to $2.55 from $2.88, below the company’s full-year consensus estimate of $3.69 per share.
• Protagonist’s latest quarterly results slightly beat expectations, with EPS of $2.29 versus $2.27 expected and revenue of $213.47 million versus $210.91 million. Revenue surged 3,746.8% year over year, while shares traded up 6.5% near their 52-week high.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and average price target of $126.71, although insiders sold 102,000 shares worth approximately $10.4 million over the past 90 days.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Research analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for Protagonist Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $2.55 per share for the quarter, down from their previous forecast of $2.88. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $3.69 per share.

Several other equities analysts have also recently issued reports on the company. Wedbush raised their price objective on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 6th. Barclays raised their price target on shares of Protagonist Therapeutics from $151.00 to $153.00 and gave the stock an "overweight" rating in a research report on Thursday. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $110.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Johnson Rice set a $165.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, July 17th. Finally, Citizens Jmp increased their price objective on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a "market outperform" rating in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $126.71.

Protagonist Therapeutics Trading Up 6.5%

Shares of NASDAQ PTGX opened at $146.18 on Friday. The company has a market capitalization of $9.40 billion, a price-to-earnings ratio of 141.92 and a beta of 1.78. Protagonist Therapeutics has a twelve month low of $50.49 and a twelve month high of $148.00. The business has a 50 day simple moving average of $123.38 and a 200-day simple moving average of $104.93.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, topping analysts' consensus estimates of $2.27 by $0.02. The company had revenue of $213.47 million for the quarter, compared to the consensus estimate of $210.91 million. Protagonist Therapeutics had a return on equity of 12.98% and a net margin of 29.40%.The company's quarterly revenue was up 3746.8% on a year-over-year basis.

Insider Activity

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company's stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the transaction, the chief executive officer owned 523,478 shares in the company, valued at approximately $52,410,617.36. This represents a 12.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the sale, the director directly owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 102,000 shares of company stock valued at $10,436,340 in the last 90 days. Insiders own 5.19% of the company's stock.

Institutional Trading of Protagonist Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its stake in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company's stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at about $27,000. Osaic Holdings Inc. lifted its holdings in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company's stock worth $65,000 after purchasing an additional 525 shares during the period. Hantz Financial Services Inc. lifted its holdings in Protagonist Therapeutics by 222.4% in the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company's stock worth $83,000 after purchasing an additional 656 shares during the period. Finally, Canton Hathaway LLC bought a new position in Protagonist Therapeutics in the 4th quarter valued at about $87,000. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source